- Home
- BW vs BMEA Comparison
BW vs BMEA Comparison
Compare BW & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BW
- BMEA
- Stock Information
- Founded
- BW 1867
- BMEA 2017
- Country
- BW United States
- BMEA United States
- Employees
- BW N/A
- BMEA N/A
- Industry
- BW Building Products
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- BW Industrials
- BMEA Health Care
- Exchange
- BW Nasdaq
- BMEA Nasdaq
- Market Cap
- BW 182.0M
- BMEA 209.8M
- IPO Year
- BW N/A
- BMEA 2021
- Fundamental
- Price
- BW $1.70
- BMEA $4.06
- Analyst Decision
- BW Strong Buy
- BMEA Buy
- Analyst Count
- BW 3
- BMEA 13
- Target Price
- BW $4.50
- BMEA $37.25
- AVG Volume (30 Days)
- BW 876.3K
- BMEA 827.4K
- Earning Date
- BW 11-12-2024
- BMEA 10-29-2024
- Dividend Yield
- BW N/A
- BMEA N/A
- EPS Growth
- BW N/A
- BMEA N/A
- EPS
- BW N/A
- BMEA N/A
- Revenue
- BW $878,224,000.00
- BMEA N/A
- Revenue This Year
- BW N/A
- BMEA N/A
- Revenue Next Year
- BW N/A
- BMEA N/A
- P/E Ratio
- BW N/A
- BMEA N/A
- Revenue Growth
- BW N/A
- BMEA N/A
- 52 Week Low
- BW $0.75
- BMEA $3.61
- 52 Week High
- BW $2.99
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- BW 40.51
- BMEA 23.76
- Support Level
- BW $1.73
- BMEA $5.55
- Resistance Level
- BW $1.91
- BMEA $6.06
- Average True Range (ATR)
- BW 0.12
- BMEA 0.49
- MACD
- BW -0.01
- BMEA -0.08
- Stochastic Oscillator
- BW 10.11
- BMEA 0.50
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.